-
Nu.Q® Technology
Our technology detects characteristic epigenetic changes in nucleosomes that occur from the earliest stages of cancer, sepsis and other diseases.
-
- Our Tests
- Human Health
-
Nu.Q® NETs
Nu.Q® NETs is a groundbreaking CE-marked diagnostic solution that clinicians can use to detect NETosis.
-
Nu.Q® Discover
Buy our Nu.Q® Discover H3.1 Research Use Only Assay
- Animal Health
-
Nu.Q® Vet Cancer Test
Nu.Q® Vet Cancer Test detects 76% of systemic cancers at 97% specificity.
Circulating H3K27 nucleosomes to monitor lung cancer patients during treatment
- Share
- Tweet
- Share on Facebook
- Share
Paper titled: Circulating H3K27 Nucleosomes to monitor Lung Cancer Patients During Treatment, a universal biomarker quantifiying the minimal residual disease (MRD) in plasma samples.
Grolleau et al 2023
Presented at AACCR 2023
Subscribe for Volition product updates.
Or, click here for Investor Updates and press releases.
"*" indicates required fields